Back to Search Start Over

Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment

Authors :
Lázaro Betancourt
György Marko-Varga
Daniel Rivas
Balazs Gyorffy
Melinda Rezeli
Johan Malm
Yutaka Sugihara
A. Marcell Szász
European Commission
Source :
Cell Biology and Toxicology, Digital.CSIC. Repositorio Institucional del CSIC, instname
Publication Year :
2018

Abstract

There is an increasing global interest to support research areas that can assist in understanding disease and improving patient care. The National Cancer Institute (NIH) has identified precision medicine-based approaches as key research strategies to expedite advances in cancer research. The Cancer Moonshot program (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative) is the largest cancer program of all time, and has been launched to accelerate cancer research that aims to increase the availability of therapies to more patients and, ultimately, to eradicate cancer. Mass spectrometry-based proteomics has been extensively used to study the molecular mechanisms of cancer, to define molecular subtypes of tumors, to map cancer-associated protein interaction networks and post-translational modifications, and to aid in the development of new therapeutics and new diagnostic and prognostic tests. To establish the basis for our melanoma studies, we have established the Southern Sweden Malignant Melanoma Biobank. Tissues collected over many years have been accurately characterized with respect to the tumor and patient information. The extreme variability displayed in the protein profiles and the detection of missense mutations has confirmed the complexity and heterogeneity of the disease. It is envisaged that the combined analysis of clinical, histological, and proteomic data will provide patients with a more personalized medical treatment. With respect to disease presentation, targeted treatment and medical mass spectrometry analysis and imaging, this overview report will outline and summarize the current achievements and status within malignant melanoma. We present data generated by our cancer research center in Lund, Sweden, where we have built extensive capabilities in biobanking, proteogenomics, and patient treatments over an extensive time period. © 2018, The Author(s).<br />Funding information This study was supported by a joint grant from Berta Kamprad Foundation, and grants from the National Research Foundation of Korea, funded by the government of Republic of Korea (MSIP; 2012M3A9D1054520, 2015K1A1A2028365, 2015M3A9C4076 321), European Union’s Horizon 2020, Interreg. Program: NYPS 20200407, BReproUnion^, and European Union Regional Development Fund, Interreg. Oresund, BMAX4ESSFUN, LU-062^.

Details

ISSN :
15736822
Volume :
35
Issue :
1
Database :
OpenAIRE
Journal :
Cell biology and toxicology
Accession number :
edsair.doi.dedup.....6fccf6c145353d4e3bfac8a6722f9f7b